摘要
Introduction: Genetic polymorphisms of some Glutathione S-Transferase (GST) which encode the enzyme responsible for the biotransformation of drugs and xenobiotics, have been associated with the risk of several pathologies that can progress to cancer such as Hepatitis B. This study aims to characterize the impact of the rs1695 polymorphism of GSTP1 gene among people with chronic Hepatitis B infection in Burkina Faso. Methods: rs1695 polymorphisms of GSTP1 gene genotyping was performed for 50 people infected with chronic Hepatitis B virus and 124 healthy people with the PCR-RFLP method. Conventional PCR was used for DNA amplification and Alw26I enzyme was used for enzymatic digestion. Results: The results show that the frequencies of AA, AG and GG genotypes are respectively 31.00%, 36.80% and 32.20% in general the study population with a mutation rate of 50.57%. However, the incidence of the AA, AG and GG genotypes are respectively 30.64%, 38.71% and 30.64% among people with chronic Hepatitis B virus infection and 32.00%, 32.00% and 36.00% among healthy people. In cases, the frequencies of the A and G alleles are 48.00% and 52.00% respectively, and in controls 50.00% each. No statistical difference was found by comparing genotypic and allelic frequencies between cases and controls (p > 0.05). Conclusion: Our study allowed us to determine the rate of GSTP1 rs1695 genotypes in the study population, cases and controls. From our analyses, GSTP1 rs1695 is not associated to chronic Hepatitis B virus infection in Ouagadougou.
Introduction: Genetic polymorphisms of some Glutathione S-Transferase (GST) which encode the enzyme responsible for the biotransformation of drugs and xenobiotics, have been associated with the risk of several pathologies that can progress to cancer such as Hepatitis B. This study aims to characterize the impact of the rs1695 polymorphism of GSTP1 gene among people with chronic Hepatitis B infection in Burkina Faso. Methods: rs1695 polymorphisms of GSTP1 gene genotyping was performed for 50 people infected with chronic Hepatitis B virus and 124 healthy people with the PCR-RFLP method. Conventional PCR was used for DNA amplification and Alw26I enzyme was used for enzymatic digestion. Results: The results show that the frequencies of AA, AG and GG genotypes are respectively 31.00%, 36.80% and 32.20% in general the study population with a mutation rate of 50.57%. However, the incidence of the AA, AG and GG genotypes are respectively 30.64%, 38.71% and 30.64% among people with chronic Hepatitis B virus infection and 32.00%, 32.00% and 36.00% among healthy people. In cases, the frequencies of the A and G alleles are 48.00% and 52.00% respectively, and in controls 50.00% each. No statistical difference was found by comparing genotypic and allelic frequencies between cases and controls (p > 0.05). Conclusion: Our study allowed us to determine the rate of GSTP1 rs1695 genotypes in the study population, cases and controls. From our analyses, GSTP1 rs1695 is not associated to chronic Hepatitis B virus infection in Ouagadougou.
作者
Tilate Lare
Lassina Traore
Marie Simone Traore
Sidnooma Véronique Zongo
Pierre Zabre
Mousso Savadogo
Fortune D. Salah
Herman Karim Sombie
Pegdwendé Abel Sorgho
Tégwindé Rebeca Compaore
Tani Sagna
Issoufou Tao
Florencia Wendkuuni Djigma
Dorcas Obiri-Yeboah
Damintoti Simplice Karou
Rogomenoma Alice Ouedraogo
Teega-Wende Clarisse Ouedraogo
Prosper Bado
Albert Théophane Yonli
Jacques Simpore
Tilate Lare;Lassina Traore;Marie Simone Traore;Sidnooma Véronique Zongo;Pierre Zabre;Mousso Savadogo;Fortune D. Salah;Herman Karim Sombie;Pegdwendé Abel Sorgho;Tégwindé Rebeca Compaore;Tani Sagna;Issoufou Tao;Florencia Wendkuuni Djigma;Dorcas Obiri-Yeboah;Damintoti Simplice Karou;Rogomenoma Alice Ouedraogo;Teega-Wende Clarisse Ouedraogo;Prosper Bado;Albert Théophane Yonli;Jacques Simpore(Laboratoire de Biologie Moléculaire et de Génétique, Université Joseph KI-ZERBO, Ouagadougou, Burkina Faso;Ecole Normale Supérieure, Ouagadougou, Burkina Faso;Laboratoire de Biologie Moléculaire-Virologie, Institut National d’Hygiène, Lomé, Togo;Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso;Centre National de la Recherche Scientifique et Technologique, Institut de Recherche en Sciences de la Santé, Ouagadougou, Burkina Faso;Institut des Sciences et de Technologies/Ecole Normale Supérieure, Koudougou, Burkina Faso;Department of Microbiology and Immunology, School of Medical Sciences, University of Cape Coast, PMB, Cape Coast, Ghana;école Supérieure des Techniques Biologiques et Alimentaires, Université de Lomé (ESTBA-UL), Lomé, Togo;Centre Universitaire de Gaoua, Université Nazi Boni, Bobo-Dioulasso, Burkina Faso)
